In patients with renal cell carcinoma, salvage therapy with nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 failure had limited efficacy with a 20% ORR and a median PFS of 4.0 months.21 Here, CD274 is linked to renal cell carcinoma.